New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 14, 2013
07:08 EDTLGNDLigand Pharmaceuticals raises 2013 EPS view to 47c-51c from 35c-39c
Consensus for 2013 EPS is 36c.
News For LGND From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
July 31, 2015
08:52 EDTLGNDAmgen results highlight Ligand royalty strength, says Roth Capital
Roth Capital notes Amgen (AMGN) reported Q2 Kyprolis sales of $119M compared to its estimate of $117M. The drug, alongside Promacta, represent the majority of Ligand's current royalty stream, the firm tells investors. It believes the growth of Kyprolis highlights Ligand's "strong core royalty bearing asset lineup." Roth keeps a Buy rating on the stock with a $135 price target.
July 30, 2015
09:01 EDTLGNDLigand enters license, supply agreement with Sanofi
Subscribe for More Information
July 24, 2015
12:44 EDTLGNDAmgen announces FDA approval of expanded Kyprolis indication
Subscribe for More Information
12:27 EDTLGNDFDA approves expanded use of Kyprolis in multiple myeloma patients
The FDA announced that on July 24 the administration approved carfilzomib, or Kyprolis, marketed by Onyx Pharmaceuticals, an Amgen (AMGN) subsidiary, in combination with lenalidomide and dexamethasone for the treatment of patients with relapsed multiple myeloma who have received one to three prior lines of therapy. The revised labeling includes new Warnings and Precautions for VTE, cardiac toxicities, acute renal failure, pulmonary toxicities, and hypertension. The increased safety risks, including mortality, for elderly patients is described. Detailed safety information in the prescribing information was also updated for use of carfilzomib monotherapy. Reference Link
09:02 EDTLGNDLigand says Revolade recommended by CHMP for EU approval for SAA
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use